1
|
Nguyen J, Tran TT, Ta TV, Ginsburg O. Abstract P3-10-04: Prevalence of pain and barriers to pain management in breast cancer survivors in Vietnam. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-10-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Breast cancer-related pain significantly affects quality of life and is well-documented in developed countries. However, little is known about the extent of breast cancer-related pain in developing countries. A study at the National Cancer Institute of Vietnam reported that 44% of breast cancer patients experienced moderate to severe pain. However, this study did not include breast cancer survivors, and little is known about the prevalence of pain and its management in this patient population.
Objectives: Determine the prevalence of pain, adequacy of pain management, and barriers to care in breast cancer survivors in Vietnam.
Methods: We administered previously validated and published symptom assessment tools (the BPI and MDASI) to 160 unselected Vietnamese women diagnosed and treated for breast cancer in 2007. Here we present a preliminary description of the results for the first 40 breast cancer survivors enrolled in this study.
Results: The most frequently reported symptoms were pain (62.5%, with 40% reporting the pain as severe), memory loss (50%), numbness/tingling (50%), sleep disturbance (45%), and appetite loss (32.5%). Only 23% reported adequate symptom management, with the costs of treatment and the false belief that no treatments existed for the pain being frequently cited as barriers to care.
Discussion: Cancer-related pain is highly prevalent in breast cancer survivors treated at the largest cancer hospital in Vietnam. The majority of patients report inadequate management of pain, often attributable to costs and false beliefs regarding pain management. Initiatives aimed at patient education and improving accessibility to pain management could significantly improve the quality of life in this patient population.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-10-04.
Collapse
Affiliation(s)
- J Nguyen
- University of Toronto, Toronto, ON, Canada; Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; National Canacer Institute, Hanoi, Viet Nam
| | - TT Tran
- University of Toronto, Toronto, ON, Canada; Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; National Canacer Institute, Hanoi, Viet Nam
| | - TV Ta
- University of Toronto, Toronto, ON, Canada; Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; National Canacer Institute, Hanoi, Viet Nam
| | - O Ginsburg
- University of Toronto, Toronto, ON, Canada; Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; National Canacer Institute, Hanoi, Viet Nam
| |
Collapse
|
2
|
Abstract
For several years, interferon alpha-1, also known as interferon alpha-D, has been studied for treatment of various viral diseases, such as hepatic fibrosis caused by hepatitis B, herpes simplex virus keratitis, and bovine respiratory diseases in calves. Currently, recombinant human interferon alpha-D (rHuIFNalphaD) is expressed intracellularly in Escherichia coli or secreted by Bacillus subtilis and Saccharomyces cerevisiae. In this report, we describe the process of obtaining a relatively high-yield secretion of biologically active recombinant rHuIFNalphaD using the Pichia pastoris system. The process produced as high as 0.7 mg of purified protein per 20 ml of shake culture of rHuIFNalphaD with better bioactivity than the commercially available rHuIFNalphaD molecule produced in E. coli.
Collapse
Affiliation(s)
- P T Liu
- Pepgen Corporation, 1255 Harbor Bay Parkway, Suite B, Alameda, CA 94502, USA
| | | | | |
Collapse
|
3
|
Abstract
Proteins with affinity to heparin under physiological conditions were isolated from bovine cerebral cortex. First, the extract of cerebral cortex was applied to a chondroitin polysulfate column under physiological conditions. Then, the pass-through fraction was applied to a heparin column. Among the bands on SDS polyacrylamide gel electrophoresis of the fraction bound to the heparin column, the major one was identified as fructose 1,6-bisphosphate aldolase (FPA), a cytosolic enzyme involved in the glycolytic pathway. The results indicated that FPA is a heparin-binding protein which exhibits no affinity to chondroitin polysulfate. The results of affinity chromatographies revealed that FPA binds to intact heparin and modified heparins desulfated at C2 OH of the iduronic acid residue or at C6 OH or C2 NH2 of the glucosamine residue. When 6-O-desulfated heparin was employed as the affinity ligand, a single peak having FPA activity was isolated from the extract of bovine cerebral cortex. By further Mono Q chromatography and Superdex gel-filtration, five isoenzymes were purified with more than 50% recovery. These isoenzymes were identified as FPA A4, A3C1, A2C2, A1C3, and C4 by native electrophoresis with and without 4 M urea and subsequent amino acid sequence analysis. The use of 6-O-desulfated heparin affinity chromatography thus facilitated the purification of FPA.
Collapse
Affiliation(s)
- T V Ta
- Department of Applied Biology, Faculty of Textile Science, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto, 606-8585, Japan
| | | | | | | | | | | | | |
Collapse
|
4
|
Ye Z, Takano R, Hayashi K, Ta TV, Kato H, Kamikubo Y, Nakahara Y, Kumeda K, Hara S. Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction. Thromb Res 1998; 89:263-70. [PMID: 9669748 DOI: 10.1016/s0049-3848(98)00017-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Heparin affinity chromatography of synthetic peptide fragments mimicking tissue factor pathway inhibitor (TFPI) indicated that the minimal heparin binding sequence consists of 12 amino acid residues located at the C-terminal tail. Within this minimal sequence, Arg-257 and Arg-259 appeared to contribute most significantly to interaction with heparin. Affinity chromatography of TFPI using immobilized heparin derivatives regiospecifically desulfated at O-6 of the glucosamine residue, N-2 of the glucosamine residue, and/or O-2 of the iduronic acid residue indicated that all the sulfate groups in heparin appeared to be required for TFPI-heparin interaction. Among them, however, the 6-O-sulfate groups appeared to make the largest contribution to the interaction, while the 2-O-sulfate groups contributed the least. In vitro experiments on the inhibition of factor Xa by TFPI enhanced with native and chemically modified heparins afforded similar results.
Collapse
Affiliation(s)
- Z Ye
- Department of Chemistry and Materials Technology, Faculty of Engineering and Design, Kyoto Institute of Technology, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|